Lion Point Capital, LP is an investment advisory firm organized as a Delaware limited partnership, formed on August 25, 2014 (together with its affiliates, “Lion Point”, “us,” or “we”). The firm is owned by its founding partner, Didric Cederholm. Lion Point registered as an investment adviser with the SEC on February 25, 2015. On April 1, 2015, Lion Point began managing the assets of Lion Point International, Ltd (the “Offshore Fund”) and Lion Point Associates, LP (the “Onshore Fund”) in a master-feeder structure. The Offshore Fund invests its assets primarily in Lion Point Mini Master, LP (the “Mini Master Fund”), which in turn invests its assets primarily in Lion Point Master, LP (the “Master Fund”). The Onshore Fund invests its assets primarily in the Master Fund. The Master Fund has a number of wholly-owned subsidiaries which have been formed for the purpose of facilitating various investments, but which do not themselves accept direct investments from investors. In managing the Master Fund, Lion Point employs a global special situations investment approach that applies a value-oriented investment philosophy to event driven and activist situations across the capital structure. We generally trade or invest in a wide variety of financial instruments, including, without limitation, stocks, bonds, bank loans, swaps, credit default swaps, options, futures, forwards, swaptions, private equity, and correlation products. Our trading mandates are extremely broad, and encompass virtually every type of asset, investment interest, security or property (real or personal) which can be traded or purchased. On July 1, 2022, Lion Point began managing the assets of Lion Point Life Sciences Partners, LP (the “Life Sciences Fund,” and together with the Offshore Fund, the Onshore Fund and the Sunshine Vehicle (as defined below), each individually or collectively, as the case may require, the “Fund” or “Funds”). The Life Sciences Fund is a special situations private investment fund exclusively focused on opportunities in life sciences companies. In managing the Life Sciences Fund, Lion Point employs a deep value-oriented investment philosophy that seeks to uncover mispriced assets in drug development and therapeutics. The Life Sciences Fund’s investment objective is to generate attractive, absolute returns through in-depth analysis and clear catalyst paths, while seeking to preserve capital through a focus on expected probable outcomes and convexity. For additional detail on the strategies and material risks of the Funds, see Item 8 below, “Methods of Analysis, Investment Strategies and Risk of Loss.” Our advisory services are tailored to the investment directives specified in the Fund’s offering and governing documents. We do not

expect to permit Investors (as defined below) to limit the types of securities or markets in which we can trade on behalf of the Funds. We have entered, and may in the future, enter into side letter agreements with certain Investors which may grant terms which differ from those outlined in the Fund’s offering and governing documents. These terms may include but are not limited to (i) satisfaction of regulatory requirements of a particular Investor, and (ii) acquisitions of interests in the Fund by our principals and employees and relatives of such persons or certain large or strategic Investors. Except with respect to our principals and employees, we generally do not provide any Investor in the Fund with fee or redemption terms that are more preferable than the fee and redemption terms generally available to any other Investor. Requests by Investors for additional information beyond what is generally provided to all Investors are considered by us on a case-by-case basis taking into consideration, among other things, the confidentiality of our proprietary information, the operational and administrative burden in complying with the information request and our fiduciary duties to the Fund and Investors. These requests for additional information generally stem from an Investor’s need to verify that it is meeting its own regulatory requirements. We provide such additional information to all Investors, or only to the requesting Investor on the condition that we determine that doing so will not give the recipient an unfair informational advantage over other Investors in the Fund. In addition to the Funds, Lion Point currently manages Sunshine SPV LLC (the “Sunshine Vehicle”), which is a co-investment vehicle that invests alongside the Funds in certain investment opportunities. As used throughout this Brochure, the terms “General Partner” and “General Partners” shall mean Lion Point Capital GP, LLC and Lion Point Capital GP III, LLC, in each case except where stated, or the context requires, otherwise. In the future, we may sponsor and manage other private investment funds or manage separate accounts (“Managed Accounts”). In this Brochure, the Funds and the Sunshine Vehicle (as well as any potential future funds and Managed Accounts we may manage) are referred to as “Clients,” and the investors in the Funds and the Sunshine Vehicle are referred to as “Investors.” The Funds and the Sunshine Vehicle that we manage (and not the Investors therein) are Clients of Lion Point. We also currently manage a proprietary account not included within the term “Client” as used herein. As of December 31, 2023, we had approximately $517,721,393 of regulatory assets under management, all of which are managed on a discretionary basis. We do not currently manage any assets on a non- discretionary basis.